1 / 4

Tasigna (nilotinib) |tasigna side effects |tasigna cost |Tasigna 150mg capsules

Inquire price of Tasigna 150mg Capsules composition of Nilotinib 150mg Capsules by Novartis Pharma, Blueberry pharmaceuticals is Worldwide Suppliers, Traders & wholesale exporter industry

sharonpaula08
Télécharger la présentation

Tasigna (nilotinib) |tasigna side effects |tasigna cost |Tasigna 150mg capsules

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Tasigna 150mg capsules Tasigna 150mg capsules are described as an orally bioavailable aminopyrimidine derivative which is contains as Bcr-Abl tyrosine kinase prohibitor containing anti- tumor activity. To overwhelmed Imatinib resistance, nilotinib which is an active substance of Tasigna 150mg capsules binds to and balance the inactive configuration of kinase domain of Abl protein of Bcr-Abl merging protein, concluding as prohibition of multiplication of Philadelphia chromosome positive advanced myeloid leukemia which is mediated by Bcr-Abl. TASIGNA 150MG PRESCRIBED FOR The prescribing information of Tasigna 150mg capsules for both pediatric and adult patients is given as follows; Patients with newly diagnosed Philadelphia chromosome positive CML-CP; patients suffered with resistance or intolerance Philadelphia positive CML-CP & CML-AP mainly in adults; & patients with resistance or intolerance Philadelphia positive CML-CP majorly in pediatric patients. For all these conditions, Tasigna 150mg capsules are indicated for both adults and pediatric with the age of greater than or equal to 1 year. Tasigna is used only after resistance occurred with prior tyrosine kinase inhibitor therapy. MECHANISM OF TASIGNA Tasigna containing Nilotinib is pharmacologically classified as Bcr-Abl tyrosine kinase inhibitor. Tasigna is used to overthrow the Imatinib resistance in advanced myelogenous leukemia condition. Nilotinib is involved in the inhibition of Bcr-Abl interceded multiplication of murine leukemia cells lines and human cell lines obtained from patients with Philadelphia positive CML. DOSAGE AND ADMINISTRATION OF TASIGNA

  2. For newly commenced ph+ CML-CP: The prescribed dose of Tasigna is 300mg should be administered orally as two times a day. For resistance or intolerance ph.+ CML-CP or CML-AP: The prescribed dose of Tasigna is 400mg should be administered as orally as two times day. IN PEDIATRIC: For newly commenced or resistance ph+ CML-CP: The prescribed dose of Tasigna for pediatrics is, 230mg/m2 should be administered orally as two times a day around 50mg dose and maximum dose should be 400mg single dose. Depending on body surface area the dose should be considered; Up to 0.32m2: 50mg for single dose; 100mg for total daily dose 0.33 to 0.54m2: 100mg for single dose; 200mg for total daily dose 0.55 to 0.76m2: 150mg for single dose; 300mg for daily dose 0.77 to 0.97m2: 200mg as single dose; 400mg as total daily dose 0.98 to 1.19m2: 250mg as single dose; 500mg as total daily dose 1.20 to 1.41m2: 300mg as a single dose; 600mg as total daily dose 1.42 to 1.63m2: 350mg as single dose; 700mg as total dose > Or equal to 1.64m2: 400mg as a single dose; 800mg as total daily dose. Interrupt or discontinue the therapy in the patients who are having hematological toxicities. Patient with increased serum amylase or lipase, bilirubin, AST; the therapy should be interrupt and monitor the levels. Continue the therapy with

  3. 400mg of Tasigna as single dose. In pediatric the dose should be 230mg/m2 as a single dose. In liver damage patients: Newly commenced ph+ CML in advanced phase; mild to moderate or severe: The dose of Tasigna reduced to 200mg as two times a day, elevates the dose as 300mg for two times a day. In resistance CML ph+ in either accelerated or chronic phase: For mild, moderate: The reduced dose is 300mg as two times a day; resume to increase as 400mg as two times a day. For severe: Reduced to 200mg as twice daily, increased to 300mg as twice daily and then resume at 400mg two times a day. For concurrent use of Tasigna with strong CYP3A4 inhibitors: The dose of Tasigna reduced to 300mg as a single dose in patients with intolerant ph+ CML or 200mg of Tasigna capsules as a single dose in patients with newly raised ph+ CML- CP. Patient is necessary to need strong CYP3A4 inhibitors, must be investigated by monitoring QT intervals frequently. Tasigna capsules should be administered on an empty stomach. Food should not be taken for at least 2 hours earlier the dose and for at least 1 hour after the dose. DRUG- DRUG INTERACTION Tasigna 150mg with strong CYP3A4inhibitors: may leads to elevate nilotinib concentration while compare to Tasigna 150mg used alone. This may lead to increase the risk of Avoid this combination or if it is necessary for the patients then reduce the dose of Tasigna. Tasigna 150mg with strong CYP3A inducers: may reduce the concentration of nilotinib which may causes loss of therapeutic effect of Tasigna. Avoid this concomitant. Tasigna 150mg solubility is regulated by pH values, while using Tasigna with gastric regulators like proton pump inhibitors may reduce the concentration of

  4. Tasigna. Avoid this co administration.If using gastric regulators with Tasigna, must administer 2 hours after or before the dose of Tasigna. In case of H2 receptor antagonist takes 10 hours after or before the dose of Tasigna. Drugs which extends the QT intervals: While using Tasigna 150mg with anti-arrhythmic drugs causes QT extension and to prevent this effect avoid this concomitant use. Contact us: Email id : info@blueberrypharma.com phone no : +91-97890 77748 (24/7 Support) Website : https://blueberrypharma.com/tasigna-150mg.php

More Related